Rhythm Pharmaceuticals, Inc.
Financials
Valuation Metrics
Rhythm Pharmaceuticals, Inc.'s Market Cap is $6.41B. At end of 2025 it was $7.16B. Ranked #1168 of 3,116 in US market (top 37%), #383 of 1,472 on NASDAQ (top 26%), #64 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 24%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $6.41B | US#1,168/3,116 Sec#64/265 |
| Revenue | $240M | US#2,502/3,116 Sec#103/265 |
| Net Income | $-205M | US—/3,116 Sec—/265 |
| Total Assets | $437M | US#2,808/3,116 Sec#173/265 |
| Net Assets | $217M | US#2,643/3,116 Sec#183/265 |
| Employees | 414 | US#2,317/3,116 Sec#91/265 |
| Value | ||
| P/B | 29.51x | US#2,842/3,116 Sec#225/265 |
| P/S | 26.73x | US#2,875/3,116 Sec#152/265 |
| FCF Yield | -2.35% | US—/3,116 Sec—/265 |
| Profitability | ||
| ROE | -94.50% | US#2,775/3,116 Sec#199/265 |
| ROA | -46.96% | US#2,973/3,116 Sec#207/265 |
| Op. Margin | -83.62% | US#2,694/3,116 Sec#117/265 |
| Revenue Growth | 53.51% | US#209/3,116 Sec#48/265 |
| Financial Health | ||
| Debt Ratio | 101.23% | US#1,111/3,116 Sec#163/265 |
| Total Debt | $4M | US#2,914/3,116 Sec#220/265 |
| FCF | $-150M | US#2,717/3,116 Sec#179/265 |
| Cash | $66M | US#2,456/3,116 Sec#207/265 |
| Current Ratio | 3.45x | US#652/3,116 Sec#172/265 |
| Performance | ||
| 1Y Return | -17.75% | US#2,379/3,116 Sec#192/265 |
| 1M Return | 0.80% | US#2,131/3,116 Sec#145/265 |
| From 52W High | -23.43% | US#1,730/3,116 Sec#103/265 |
| 1Y MDD | -35.54% | US#1,682/3,116 Sec#96/265 |
| Trading | ||
| Volume | 1,631,033 shares | US#1,871/3,116 Sec#189/265 |
| Trading Value | $153M | US#1,188/3,116 Sec#79/265 |
| Per Share | ||
| EPS | $-3.00 | US—/3,116 Sec—/265 |
| BPS | $3.17 | US#2,463/3,116 Sec#158/265 |
Company Info
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial products, dedicated to the discovery, development, and market launch of therapies addressing rare genetic conditions that cause obesity. Its leading pharmaceutical, IMCIVREE, functions as a powerful agonist of the melanocortin-4 receptor (MC4R). This medication is indicated for treating obesity stemming from deficiencies in pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or the leptin receptor (LEPR), alongside its use in patients with Bardet-Biedl and Alström syndromes. Furthermore, the company is progressing setmelanotide (the active compound in IMCIVREE) through Phase II clinical trials. These studies are evaluating its potential for a broader spectrum of applications, including obesity caused by heterozygous POMC or LEPR deficiencies, steroid receptor coactivator 1 (SRC1) deficiency, SH2B1 deficiency, MC4 receptor deficiency, and obesity associated with Smith-Magenis syndrome, POMC epigenetic disorders, and other MC4R-related conditions. Rhythm Pharmaceuticals holds a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The firm, headquartered in Boston, Massachusetts, was established in 2008 and changed its name from Rhythm Metabolic, Inc. to Rhythm Pharmaceuticals, Inc. in October 2015.